| Biovest Meets Skeptic's Requirements for 'The Next Dendreon' - Part 3 James Hill, MD submits: This series investigates how the BiovaxID lymphoma vaccine may win FDA approval to make Biovest (BVTI.PK) “the next Dendreon,” according to criteria elaborated in David Miller’s Minyanville article of the same name. Dendreon (DNDN), you will recall, is the first company ever to achieve FDA approval of a cancer vaccine, with it flagship product, Provenge (sipuleucel-T). Part 1 of this article dealt with vaccine manufacturing issues, Part 2 with multi-antigen targeting by cancer vaccines.Complete Story » seekingalpha.com |
Alliance Healthcare downgraded on imaging, prices (AP) An RBC Capital Markets analyst downgraded shares of Alliance Healthcare Services Inc. Thursday, saying its diagnostic imaging volume will stay low due to the weak economy, and Medicare reimbursement should remain under pressure. us.rd.yahoo.com |
Do Not Get Caught Short Small or Mid Cap Tech There’s a very simple equation taking place in this market right now and I wouldn’t be fighting against it. Here’s how it goes. Big cap tech firms have an enormous amount of cash on their balance sheets and are coming off some of the best couple of quarters they’ve ever had. Growth has been very good for these companies, but they are obviously scared that in a weakening domestic economy it may be hard to keep up the page organically.Complete Story » seekingalpha.com |
CellDex Therapeutics Gets Hammered After Divorce With Pfizer, Time to Buy? VFC submits: Shares of CellDex Thereapeutics (CLDX) were slammed late last week after Pfizer (PFE) backed out of an over two-year-old licensing agreement for CDX-110, a cancer vaccine currently being tested for effectiveness in fighting one of the most aggressive forms of brain cancer. CDX-110 is CellDex's most advanced product candidate, currently being evaluated in the later stages of an ongoing Phase II trial. After having traded near ten dollars over the past year, CLDX collapsed to below the three dollar mark for a brief time on Friday, before recovering somewhat to settle in the mid three dollar range. Over seven million shares traded hands, signifcantly higher than the average of roughly 600,000, and the company's market cap closed last week at 112.56 million.Complete Story » seekingalpha.com |
Genomic Health to Announce Third Quarter 2010 Financial Results and Host Conference Call on Monday, November 8, 2010 [PR Newswire] - Genomic Health, Inc. today announced that the company will host a conference call and webcast on Monday, November 8 at 4:30 p.m. Eastern Time to discuss its third quarter 2010 financial results. us.rd.yahoo.com |